A practical reference on thymalfasin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-11 and is reviewed periodically as new material appears.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
== Signs and symptoms == Symptoms seen on plants infected with this virus can vary depending on the plant. However typical symptoms include vein clearing, mottling, and necrotic lines or etching. Symptoms can occur on leaves and fruit and the plants can become stunted. Like other potyviruses, TEV makes viral inclusions that can be seen in the light microscope if properly stained. This particular potyvirus makes two kinds of inclusions that can be diagnostic in a known host. One of the inclusions is the cylindrical inclusions found in the cytoplasm of infected cells and the second inclusion is found in the nucleus. Neither inclusion type stains in the nucleic acid stain (AzureA). (Inclusions of tobacco etch virus in various hosts.)
In 1870, German physicians Gustav Fritsch and Eduard Hitzig reported the modulation of brain activity in dogs by electrical stimulation of the motor cortex. In 1887, Spanish neuroanatomist professor Santiago Ramón y Cajal improved the Golgi's method of visualizing nervous tissue under light microscopy by using a technique he termed "double impregnation". He discovered a number of facts about the organization of the nervous system: the nerve cell as an independent cell, insights into degeneration and regeneration, and ideas on brain plasticity.
=== Diabetes === The diabetes management manufacturing and sales division of Medtronic is based on the perimeter of the California State University, Northridge campus in Northridge, California. The original company, Minimed Technologies, was founded in 1983 by Alfred E. Mann and spun off from Pacesetter Systems to design and market an open loop insulin pump. The MiniMed 502 was one of the first lightweight insulin pumps on the market, and it helped bring insulin pump usage to the mainstream market. In 1992, the MiniMed 506 was a major redesign to make it more appealing to consumers. The new design was met by boosted adoption rate, and sales increased by 357%. In 2001, Medtronic purchased Minimed, to form Medtronic Minimed. On 11 May 2009, Medtronic announced it had chosen San Antonio, Texas, for the location of its new Diabetes Therapy Management and Education Center. The company announced that it expected 1400 new jobs would be created to staff the 150,000-square-foot (14,000 m2) facility. In September 2016, the FDA approved a device, the MiniMed 670G which was launched in 2017. It was the world's first Hybrid Closed Loop system for people with type 1 diabetes. Featuring the company's advanced algorithm - SmartGuard technology and glucose sensor - Guardian™ Sensor 3, it was the first insulin pump approved by the Food and Drug Administration (FDA) that enabled personalized and automated* delivery of basal insulin, the background insulin needed to maintain stable blood sugar levels throughout the day and night.
== Resources == Casss Times Archived 2006-09-28 at the Wayback Machine, Spring 2005 Casss Times Archived 2006-09-28 at the Wayback Machine, Autumn 2005 California Death Index Robert G Brownlee Marine project Archived 2014-04-15 at the Wayback Machine Article in The Scientist, June 1990 Applied Biosystems Timeline
== Mode of action == Kurtoxin inhibits ion calcium channels by modifying channel gating. The effect of the toxin is voltage-dependent. In a voltage-clamp experiment, it was found that calcium channels are more strongly inhibited by minor depolarization than by a strong depolarization of the cell. The peptide toxin binds close to the channel voltage sensor, and thereby produces complex gating modifications specific for each channel type. In rats, kurtoxin inhibited T-type, L-type, and N-type Ca channels and facilitated P-type channels. Deactivation was accelerated in T-type and L-type channels, slowed down in P-type channels, and not affected in N-type calcium channels. Kurtoxin also has an effect on sodium channels. It slows down both activation and inactivation of the channel.
Sources: en.wikipedia.org
=== Muscle Media 2000 ("MM2K") === In 1992, Phillips moved out of his mother's home and changed the publication's format and name to Muscle Media 2000 (usually referred to as "MM2K"). The magazine published frank discussion of the underground aspects of bodybuilding such as the use of and how to smuggle steroids, and columns by writers such as The Steroid Guru Dan Duchaine, Editor-in-Chief TC Luoma, Charles Poliquin, Mike Mooney, Nutritionist Keith Klein CN CCN, and Michael Dullnig M.D. aka "Dr. X." Muscle Media 2000 debuted in March 1992 and featured bodybuilder Lee Labrada on the cover.
1993/3045) Broadcasting (Prescribed Countries) (Amendment) Order 1993 (S.I. 1993/3046) Broadcasting (Foreign Satellite Programmes) (Specified Countries) (Amendment) Order 1993 (S.I. 1993/3047) Road Vehicles (Construction and Use) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/3048) Public Lending Right Scheme 1982 (Commencement of Variation) Order 1993 (S.I. 1993/3049) Notification of New Substances Regulations 1993 (S.I. 1993/3050) Hearing Aid Council Monetary Penalty (Increase) Order 1993 (S.I. 1993/3052) Commercial Agents (Council Directive) Regulations 1993 (S.I. 1993/3053) Local Authorities (Capital Finance) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/3054) Income Tax (Interest Relief) (Qualifying Lenders) (No. 4) Order 1993 (S.I. 1993/3055) Education (University Commissioners) Order 1993 (S.I. 1993/3056) National Health Service Trusts (Consultation on Dissolution) (Scotland) Regulations 1993 (S.I. 1993/3057) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) (No.2) (Partial Revocation No.2) Order 1993 (S.I. 1993/3058) Non-Domestic Rating Contributions (Scotland) Amendment Regulations 1993 (S.I. 1993/3059) New Town (Livingston) Winding Up Order 1993 (S.I. 1993/3060) New Town (Irvine) Winding Up Order 1993 (S.I. 1993/3061) New Town (Cumbernauld) Winding Up Order 1993 (S.I. 1993/3062) Herring (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3063) Passenger and Goods Vehicles (Recording Equipment) (Approval of Fitters and Workshops) (Fees) (Amendment) Regulations 1993 (S.I.
Kendall was elected to the United States National Academy of Sciences in 1950, and both the American Academy of Arts and Sciences and the American Philosophical Society in 1951. Kendall's career at Mayo ended in 1951, when he reached mandatory retirement age. He moved on to Princeton University, where he was a visiting professor in the Department of Biochemistry. He remained affiliated with Princeton until his death in 1972. In addition to the Nobel Prize, Kendall received other major awards including the Lasker Award, the Passano Foundation Award and the Cameron Prize for Therapeutics of the University of Edinburgh. Kendall received the Golden Plate Award of the American Academy of Achievement in 1966. He was awarded honorary doctorates from the University of Cincinnati, Western Reserve University, Williams College, Yale University, Columbia University, National University of Ireland, and Gustavus Adolphus College.
== Mechanism == The substrates for the peptidyl transferase reaction are two tRNA molecules: one in the peptidyl site, bearing the growing peptide chain, and the other in the aminoacyl site, bearing the amino acid that will be added to the chain. The peptidyl chain and the incoming amino acid are attached to their respective tRNAs via ester bonds to the oxygen atom at the 3' ends of these tRNAs. The 3' ends of all tRNAs share a universally conserved CCA sequence. The alignment between the CCA ends of the ribosome-bound peptidyl tRNA and aminoacyl tRNA in the peptidyl transferase center contribute to peptide bond formation by providing the proper orientation for the reaction to occur. This reaction occurs via nucleophilic displacement. The amino group of the aminoacyl tRNA attacks the terminal carbonyl group of the peptidyl tRNA. The reaction proceeds through a tetrahedral intermediate and the loss of the P site tRNA as a leaving group. In peptidyl-tRNA hydrolysis, the same mechanism is used, but with a water molecule as the nucleophile.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.